# Katayoun Rezvani

Source: https://onco.cc/people/katy-rezvani/  
OnCo record `katy-rezvani` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Created cord blood-derived CAR-NK cells, the first off-the-shelf CAR cell therapy to show remissions in lymphoma.

## Summary

Katy Rezvani led the development and first-in-human trial of CD19-directed CAR natural killer cells derived from cord blood, which produced remissions in most patients with relapsed CLL and lymphoma without cytokine release syndrome or graft-versus-host disease, establishing NK cells as an allogeneic platform. Her laboratory engineers NK cells against solid tumour and myeloid targets and she directs the cell therapy programme at MD Anderson.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cell-therapy; nk-cells; off-the-shelf
- Role: Professor of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center
- Specialisms: CAR-NK cell therapy; Cord blood-derived cell therapy; Allogeneic immunotherapy; Transplant immunology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Rezvani%20K%5BAuthor%5D%20CAR%20NK

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- journals: [Leukemia](https://onco.cc/journals/leukemia/)

---
JSON: https://onco.cc/api/v1/entities/katy-rezvani.json